Published in final edited form as:

Org Lett. 2013 October 4; 15(19): . doi:10.1021/ol402444a.

Synthesis of Plantazolicin Analogues Enables Dissection of Ligand Binding Interactions of a Highly Selective Methyltransferase

Abhishek Sharma¹, Patricia M. Blair¹, and Douglas A. Mitchell^{1,2,3}

Douglas A. Mitchell: douglasm@illinois.edu

¹Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois, 61801, USA

²Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, 61801, USA

³Department of Microbiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, 61801, USA

Abstract

A convergent strategy for the synthesis of truncated analogues of plantazolicin (PZN), a member of the thiazole/oxazole-modified microcin (TOMM) class of natural products, has been developed. These *N*-terminal mono-, tri- and pentazole substructures of PZN were utilized to probe the substrate requirements and thermodynamic ligand binding parameters of an unusually selective PZN methyltransferase (BamL) by isothermal titration calorimetry. Our results demonstrate that the presence of a single *N*-terminal azole permits efficient processing by BamL; however, the substrate binding becomes stronger with increased polyazole chain length.

Plantazolicin (PZN, **1**, Fig. 1)¹ is a member of the thiazole/oxazole-modified microcin² (TOMM) class of natural products and is produced by select strains of *Bacillus amyloliquefaciens* and *Bacillus pumilus*. PZN possesses highly discriminating antibacterial action against *Bacillus anthracis*, the causative agent of anthrax.^{1b} The biosynthesis of PZN involves the post-translational modification of a 41-residue precursor peptide into a polyazole framework (desmethylPZN) via heterocyclization of Cys, Ser and Thr residues. Subsequent leader peptide cleavage, followed by *N*-terminal dimethylation at Arg, affords the product.^{1a} Our previous studies^{1a,3} on the biosynthesis of PZN have led to the identification and structural elucidation of a highly selective, *S*-adenosyl-L-methionine (SAM)-dependent-methyltransferase (BamL) which only methylates the *N*-terminus of compounds highly similar to desmethylPZN. Intriguingly, Arg-containing tetrapeptides,

Correspondence to: Douglas A. Mitchell, douglasm@illinois.edu.

Supporting Information Available: Experimental procedures, characterization data for compounds and details of enzyme assays. This material is free of charge via the internet at <http://pubs.acs.org>

meant to serve as substrate mimics (RGGG, RAAA), were also unprocessed by BamL,³ which is unusual behavior for a tailoring methyltransferase.⁴

Motivated by the remarkable preference of BamL for the Arg-polyazole framework of desmethylPZN, we initiated studies towards a modular synthesis of truncated analogues of PZN. X-ray crystallographic analysis of BamL in complex with S-adenosyl-L-homocysteine (SAH) revealed a deep, narrow tunnel running from the surface of the protein to the active site.³ As the length of this tunnel is sufficient to accommodate the first 4–5 residues of desmethylPZN, while its narrowness would exclude uncyclized peptides, we hypothesized that it served as the desmethylPZN-binding pocket. Therefore, we envisioned three different Arg-(poly)azole fragments (Fig. 1, **2–4**) of increasing length and complexity as putative substrates for probing BamL activity and selectivity. Our synthetic strategy was designed to enable access to sufficient quantities of a panel of biosynthetically inaccessible PZN variants.⁵ Such a function-oriented approach⁶ would allow us to characterize the relative effect of adding heterocycles to the N-terminal framework on BamL-dependent binding and methylation. The envisaged variants were also expected to offer practical utility, as their increased aqueous solubility would facilitate biochemical assays such as isothermal titration calorimetry (ITC) studies with BamL, which was otherwise not possible with the poorly soluble natural substrate, desmethylPZN.³ In the course of our above work, the Süssmuth group reported the total synthesis of PZN.⁷

Herein, we disclose a convergent synthesis of various PZN analogues and demonstrate their utility to probe the substrate specificity and thermodynamic parameters of BamL activity using ESI-MS endpoint and ITC binding assays.

Retrosynthetic analysis of the targeted PZN analogues (**2–4**, Fig. 1), with a goal of a convergent synthetic design, led to the identification of three azole building blocks (**5–7**, Fig. 1), wherein, the latent functional groups were strategically masked by mutually orthogonal protecting groups.⁸ Moreover, one of the building blocks (Arg-Thz, **5**, Fig. 1) in its deprotected form also serves as our simplest synthetic target (**2**, Fig. 1).

The synthesis of **2** began with the HCTU/HOBt-promoted coupling of Fmoc-Arg(Pbf)-OH (**9**, Pbf = 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl) with Fmoc-Cys(Trt)-OAllyl (**8**, Scheme 1). The resulting dipeptide **10** was subjected to a one-pot Trt-deprotection and cyclodehydration using Tf₂O/PPh₃O⁹ to yield the respective thiazoline. Unfortunately, the chromatographic separation of this highly polar thiazoline from PPh₃O was difficult due to similar retention factors. Gratifyingly, a one-pot procedure proved useful, wherein after cyclodehydration, the thiazoline was immediately oxidized with MnO₂ to afford the thiazole (**5a**). Unlike the thiazoline, thiazole **5a** was readily separable from PPh₃O (25% yield). Subsequent Fmoc deprotection of **5a**, followed by cleavage of the Pbf group in the presence of TFA:TIPS:H₂O (94:3:3), furnished **2**, our first truncated target. Although we were able to obtain **5a** by a one-pot cyclodehydration-oxidation, the relatively low yield, coupled with a necessity for sufficient quantities for further chain-elongation steps, led us to adopt the Hantzsch route¹⁰ for the synthesis of related Boc-protected analogue **5b** (Supporting Information).

Progressing into the next phase of synthesis (Scheme 2), deprotection of the acetonide-Boc motif of thiazole building block **6a** (Supporting Information) revealed the HCl salt of amino alcohol **6b**. In parallel, the ethyl ester of **5b** was hydrolyzed to carboxylic acid **5c**, which was condensed with **6b** using HCTU/HOBt and DIEA. The resulting bisthiazole intermediate **11** was subjected to cyclodehydration by employing Deoxo-fluor,¹¹ followed by oxidation with BrCCl₃/DBU to afford the triazole (**12**). Finally, simultaneous

deprotection of the *N*-Boc and Pbf groups by TFA:TIPS:H₂O furnished the desired triazole analogue (**3**).

Next, we turned our attention to the construction of the complete left hand fragment of desmethylPZN. The synthesis commenced with the oxazole building block **7a**, (Supporting Information) whose treatment with HCl revealed the free amino alcohol **7b** (Scheme 3). In parallel, the thiazole ester was saponified to its carboxylic acid (**6c**). The two fragments (**7b** and **6c**) were then condensed by the action of HCTU/HOBt and DIEA into the bisazole hydroxy amide (**13**). Cyclodehydration of **13** by Deoxo-fluor at –20 °C installed the oxazoline residue, which was oxidized with BrCCl₃/DBU (4.2 equiv, 48 h) to give **14**. Treatment of **14** with HCl (4 M, 1,4-dioxane) unmasked the amino alcohol, which was subsequently coupled to **5c**. The resulting tetrazole hydroxy amide **15** was subjected to sequential cyclodehydration-oxidation to furnish the contiguous pentazole framework **16**. In the final step, acid induced dismantling of the *N*-Boc and Pbf groups gave the desired left hand fragment of desmethylPZN (**4**).

With the mono-, tri-, and pentazole *N*-terminal PZN analogues in hand, we first evaluated whether these compounds were substrates for BamL. Each analogue (**2–4**) was screened for conversion into the respective methylated product by treatment with BamL in the presence of SAM. Like desmethylPZN, all three were found to be dimethylated by BamL (as determined by ESI-MS/HRMS and LC-MS, Supporting Information) after a 16 h endpoint assay (condition A, Supporting Information). Under these conditions, **3** gave full conversion, while **2** and **4** left detectable levels of unconverted starting material. A more stringent 1 h assay with lower concentrations of enzyme and substrate (condition B, Supporting Information) was also conducted to obtain greater resolution into the relative substrate efficiencies. As expected with condition B, we observed decreases in peak intensity by ESI-MS for all of the dimethylated products relative to condition A. However, this decrease was substantially greater for reactions with **2** and **4**, as reaction with **3** was nearly complete under condition B (Supporting Information). This suggests that while the presence of one azole is sufficient for BamL processing, the reaction efficiency increases substantially when the substrate has three azole rings (**3**).

To gain deeper insight into the binding interaction of **2–4** with BamL, we conducted a series of ITC binding assays (Fig. 2). While we obtained binding curves for the monoazole (**2**, $K_d = 2.2 \mu\text{M}$) and triazole fragments (**3**, $K_d = 1.7 \mu\text{M}$), the limited aqueous solubility of pentazole **4** resulted in unreliable data. The addition of an organic cosolvent (*i.e.* 2% *v/v* DMSO) solubilized **4**, yet the ITC binding curve was uninterpretable.¹² This poor solution behavior of **4** paralleled the highly hydrophobic desmethylPZN, which also yielded uninterpretable data by ITC.³ Our results underscore the benefit of using small molecule synthesis to probe complex protein-substrate interactions.

Previously, we reported that an even more minimal structure, Arg-NH₂ (**17**), was inefficiently converted to (CH₃)₂-Arg-NH₂ by BamL.³ We again employed ITC to evaluate binding to BamL and measured a K_d of 225 nM (Fig. 2c and Supporting Information). It is noteworthy that addition of a single thiazole to Arg-NH₂ (**2** vs. **17**) increased the affinity for BamL by two orders of magnitude. Analysis of the Gibbs free energy terms indicated that the stronger interaction obtained with **3** as compared to **2** was primarily entropically driven. The ITC data also show that differences in BamL affinity were not solely responsible for the enhanced processing of **3** compared to **2**.

In conclusion, we have disclosed a convergent synthesis of biosynthetically inaccessible analogues of PZN comprising the Arg-mono-, tri- and -pentazole frameworks. The developed building block approach utilizes a strategic combination of Deoxo-fluor-

promoted cyclodehydration and Hantzsch thiazole synthesis to install azoles on a peptide backbone. The synthetic PZN analogues enabled the interrogation of ligand binding interactions with BamL, an unusually selective small molecule methyltransferase. All three synthetic fragments were dimethylated in a SAM- and BamL-dependent fashion. ITC studies indicated that the triazole fragment (**3**) possessed marginally higher affinity for BamL than the monoazole (**2**). Due to their superior aqueous solubility compared to desmethylPZN, the synthesized PZN analogues may be more suitable ligands for X-ray crystallography studies with BamL.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank members of the Mitchell lab for critical review of this manuscript. This work was supported in part by the National Institutes of Health Director's New Innovator Award program (DP2 OD008463 to D.A.M.).

References

1. (a) Scholz R, Molohan KJ, Nachtigall J, Vater J, Markley AL, Süssmuth RD, Mitchell DA, Borriess R. *J Bacteriol.* 2011; 193:215–224. [PubMed: 20971906] (b) Molohan KJ, Melby JO, Lee J, Evans BS, Dunbar KL, Bumpus SB, Kelleher NL, Mitchell DA. *ACS Chem Biol.* 2011; 6:1307–1313. [PubMed: 21950656] (c) Kalyon B, Helaly SE, Scholz R, Nachtigall J, Vater J, Borriess R, Süssmuth RD. *Org Lett.* 2011; 13:2996–2999. [PubMed: 21568297]
2. (a) Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, Bulaj G, Camarero JA, Campopiano D, Challis JGL, Clardy J, Cotter PD, Craik DJ, Dawson M, Dittmann E, Donadio S, Dorrestein PC, Entian KD, Fischbach MA, Garavelli JS, Goransson U, Gruber CW, Haft DH, Hemscheidt TK, Hertweck C, Hill C, Horswill AR, Jaspars M, Kelly WL, Klinman JP, Kuipers OP, Link AJ, Liu W, Marahiel MA, Mitchell DA, Moll GN, Moore BS, Muller R, Nair SK, Nes IF, Norris GE, Olivera BM, Onaka H, Patchett ML, Piel J, Reaney MJT, Rebuffat S, Ross RP, Sahl HG, Schmidt EW, Selsted ME, Severinov K, Shen B, Sivonen K, Smith L, Stein T, Süssmuth RD, Tagg JR, Tang GL, Truman AW, Vederas JC, Walsh CT, Walton JD, Wenzel SC, Willey JM, van der Donk WA. *Nat Prod Rep.* 2013; 30:108–160. [PubMed: 23165928] (b) Lee SW, Mitchell DA, Markley AL, Hensler ME, Gonzalez D, Wohlrab A, Dorrestein PC, Nizet V, Dixon JE. *Proc Natl Acad Sci USA.* 2008; 105:5879–5884. [PubMed: 18375757] (c) Melby JO, Nard NJ, Mitchell DA. *Curr Opin Chem Biol.* 2011; 15:369–378. [PubMed: 21429787]
3. Lee J, Hao Y, Blair PM, Melby JO, Agarwal V, Burkhart BJ, Nair SK, Mitchell DA. *Proc Natl Acad Sci USA.* 2013; 110:12954–12959. [PubMed: 23878226]
4. (a) Zhang Q, Van der Donk WA. *FEBS Lett.* 2012; 586:3391–3397. [PubMed: 22841713] (b) Luo M. *ACS Chem Biol.* 2012; 7:443–463. [PubMed: 22220966] (c) Winter JM, Chiou G, Bothwell IR, Xu W, Garg NK, Luo M, Tang Yi. *Org Lett.* 2013; 15:3774–3777. [PubMed: 23837609] (d) Zhang C, Weller RL, Thorson JS, Rajski SR. *J Am Chem Soc.* 2006; 128(9):2760–2761. [PubMed: 16506729]
5. Deane CD, Melby JO, Molohan KJ, Susarrey AR, Mitchell DA. *ACS Chem Biol.* 2013; 10:1021/cb4003392
6. Wender PA, Verma VA, Paxton TJ, Pillow TH. *Acc Chem Res.* 2008; 41:40–49. [PubMed: 18159936]
7. Banala S, Ensle P, Süssmuth RD. *Angew Chem Int Ed.* 2013; 52:9518–9523.
8. Garner P, Park JM. *J Org Chem.* 1987; 52:2361–2364.
9. You SL, Razavi H, Kelly JW. *Angew Chem Int Ed.* 2003; 42:83–85.
10. (a) Nicolaou KC, Safina BS, Zak M, Lee SH, Nevalainen M, Bella M, Estrada AA, Funke C, Zecri FJ, Bulat S. *J Am Chem Soc.* 2005; 127:11159–11175. [PubMed: 16076224] (b) Merritt EA, Bagley MC. *Synthesis.* 2007:3535–3541.

11. (a) Lal GS, Pez GP, Pesaresi RJ, Prozonic FM, Cheng HS. J Org Chem. 1999; 64:7048–7054.(b) Phillips AJ, Uto Y, Wipf P, Reno MJ, Williams DR. Org Lett. 2000; 2:1165–1168. [PubMed: 10804580]
12. The use of 2–2.5% *v/v* DMSO as a co-solvent did not lead to inactivation of BamL, as evidenced by extensive dimethylation of **4** under reaction condition A (Supporting Information).

Figure 1.
Structure of plantazolicin (1), its envisaged analogues (2–4) and their retrosynthesis into building blocks (5–7)

Figure 2.

ITC data and fitting curves for the binding of **2** (a) and **3** (b), the thermodynamic parameters of binding for the ITC titration of PZN analogues (**2–3**) and Arg-NH₂ (**17**) with BamL (c), and a model of the tunnel depicting the binding site for PZN analogues (d).

Scheme 1.

Scheme 2.

Scheme 3.